Latest News and Press Releases

NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...

NEWARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...

Sustained anti-cholestatic and hepatoprotective effects observed in patients with and without cirrhosisSelf-reported pruritus improved at one year for patients in highest categories of baseline...

NEWARK, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...

FDA lifts all clinical holds on seladelpar Positive topline data announced from ENHANCE Company to reinitiate clinical development of seladelpar for patients with PBC Cash sufficient to fund...

NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...

The study demonstrated seladelpar to be efficacious, safe and well-tolerated78.2% of patients on seladelpar 10 mg versus 12.5% on placebo achieved the primary composite outcome after only 3 months...

Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC  Re-initiating clinical development focusing first on Phase 3 for PBC NEWARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- CymaBay...

Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC Improvements in other quality-of-life parameters also...

NEWARK, Calif., June 05, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY),  a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...